PLRX vs. ANNX, FGEN, GLPG, ARVN, IDYA, MRUS, ADMA, RYTM, MLTX, and APGE
Should you be buying Pliant Therapeutics stock or one of its competitors? The main competitors of Pliant Therapeutics include Annexon (ANNX), FibroGen (FGEN), Galapagos (GLPG), Arvinas (ARVN), IDEAYA Biosciences (IDYA), Merus (MRUS), ADMA Biologics (ADMA), Rhythm Pharmaceuticals (RYTM), MoonLake Immunotherapeutics (MLTX), and Apogee Therapeutics (APGE). These companies are all part of the "medical" sector.
Annexon (NASDAQ:ANNX) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, valuation, community ranking, earnings, analyst recommendations and dividends.
Annexon has higher earnings, but lower revenue than Pliant Therapeutics.
Pliant Therapeutics received 20 more outperform votes than Annexon when rated by MarketBeat users. However, 74.60% of users gave Annexon an outperform vote while only 72.04% of users gave Pliant Therapeutics an outperform vote.
In the previous week, Annexon and Annexon both had 3 articles in the media. Annexon's average media sentiment score of 1.61 beat Pliant Therapeutics' score of 0.37 indicating that Pliant Therapeutics is being referred to more favorably in the news media.
97.3% of Pliant Therapeutics shares are owned by institutional investors. 12.7% of Annexon shares are owned by insiders. Comparatively, 6.4% of Pliant Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Annexon's return on equity of -35.08% beat Pliant Therapeutics' return on equity.
Annexon currently has a consensus price target of $15.33, suggesting a potential upside of 145.73%. Pliant Therapeutics has a consensus price target of $45.38, suggesting a potential upside of 239.38%. Given Annexon's higher probable upside, analysts plainly believe Pliant Therapeutics is more favorable than Annexon.
Annexon has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500. Comparatively, Pliant Therapeutics has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500.
Summary
Pliant Therapeutics beats Annexon on 8 of the 12 factors compared between the two stocks.
Get Pliant Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PLRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pliant Therapeutics Competitors List
Related Companies and Tools
